Sputum periostin is a biomarker of type 2 inflammation but not airway dysfunction in asthma
- PMID: 36914406
- PMCID: PMC10257949
- DOI: 10.1111/resp.14491
Sputum periostin is a biomarker of type 2 inflammation but not airway dysfunction in asthma
Keywords: IL-13; IL-4; IL-5; airway hyperresponsiveness; asthma; periostin; type-2.
Conflict of interest statement
Conflict of Interest Statement
T.A.-S. has a patent MicroRNAs as Predictors of Response to Anti-IgE Therapies in Chronic Spontaneous Urticaria pending. C.W.F., J.S.D., S.F.Z., and T.S.H report grants from the National Institute of Health during the conduct of the study. M.C.P. reports grants from National Institute of Health-NHLBI, Boeringer-Ingelheim, Astrazeneca, Boehringer-Ingelheim, Genentech, GlaxoSmithKline, Sanofi-Genzyme-Regeneron, and Teva, outside the submitted work. K.W., G.J., and C.T.J.H. are employees of Genentech. All other authors declared no conflict of interest.
References
-
- Bobolea I, Barranco P, Del Pozo V, Romero D, Sanz V, Lopez-Carrasco V, et al. Sputum periostin in patients with different severe asthma phenotypes. Allergy. 2015; 70: 540–6. - PubMed
